Cargando…

Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis

Hemodialysis is a modality of blood filtration in which accumulated toxins and water are removed from the body. This treatment is indicated for patients at the end stage of renal disease. Vascular access complications are responsible for 20–25% of all hospitalizations in dialyzed patients. The occur...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios, Danyelle Romana Alves, Pinheiro, Melina Barros, de Oliveira Junior, Wander Valadares, Braga Gomes, Karina, Carvalho, Andréa Teixeira, Martins-Filho, Olindo Assis, Simões e Silva, Ana Cristina, Dusse, Luci Maria Sant'Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551539/
https://www.ncbi.nlm.nih.gov/pubmed/28819334
http://dx.doi.org/10.1155/2017/9678391
_version_ 1783256321522401280
author Rios, Danyelle Romana Alves
Pinheiro, Melina Barros
de Oliveira Junior, Wander Valadares
Braga Gomes, Karina
Carvalho, Andréa Teixeira
Martins-Filho, Olindo Assis
Simões e Silva, Ana Cristina
Dusse, Luci Maria Sant'Ana
author_facet Rios, Danyelle Romana Alves
Pinheiro, Melina Barros
de Oliveira Junior, Wander Valadares
Braga Gomes, Karina
Carvalho, Andréa Teixeira
Martins-Filho, Olindo Assis
Simões e Silva, Ana Cristina
Dusse, Luci Maria Sant'Ana
author_sort Rios, Danyelle Romana Alves
collection PubMed
description Hemodialysis is a modality of blood filtration in which accumulated toxins and water are removed from the body. This treatment is indicated for patients at the end stage of renal disease. Vascular access complications are responsible for 20–25% of all hospitalizations in dialyzed patients. The occurrence of thrombosis in the vascular access is a serious problem that may severely compromise or even make the hemodialysis impossible, which is vital for the patient. The aim of this study was to investigate inflammatory profile in patients undergoing hemodialysis as well as the association between these alterations and vascular access thrombosis. A total of 195 patients undergoing hemodialysis have been evaluated; of which, 149 patients had not experienced vascular access thrombosis (group I) and 46 patients had previously presented this complication (group II). Plasma levels of cytokines including interleukin (IL-) 2, IL-4, IL-5, IL-10, TNF-α, and IFN-γ were measured by cytometric bead array. Our results showed that patients with previous thrombotic events (group II) had higher levels of the IL-2, IL-4, IL-5, and IFN-γ when compared to those in group I. Furthermore, a different cytokine signature was detected in dialyzed patients according to previous occurrences or not of thrombotic events, suggesting that elevated levels of T-helper 1 and T-helper 2 cytokines might, at least in part, contribute to this complication.
format Online
Article
Text
id pubmed-5551539
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55515392017-08-17 Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis Rios, Danyelle Romana Alves Pinheiro, Melina Barros de Oliveira Junior, Wander Valadares Braga Gomes, Karina Carvalho, Andréa Teixeira Martins-Filho, Olindo Assis Simões e Silva, Ana Cristina Dusse, Luci Maria Sant'Ana Dis Markers Research Article Hemodialysis is a modality of blood filtration in which accumulated toxins and water are removed from the body. This treatment is indicated for patients at the end stage of renal disease. Vascular access complications are responsible for 20–25% of all hospitalizations in dialyzed patients. The occurrence of thrombosis in the vascular access is a serious problem that may severely compromise or even make the hemodialysis impossible, which is vital for the patient. The aim of this study was to investigate inflammatory profile in patients undergoing hemodialysis as well as the association between these alterations and vascular access thrombosis. A total of 195 patients undergoing hemodialysis have been evaluated; of which, 149 patients had not experienced vascular access thrombosis (group I) and 46 patients had previously presented this complication (group II). Plasma levels of cytokines including interleukin (IL-) 2, IL-4, IL-5, IL-10, TNF-α, and IFN-γ were measured by cytometric bead array. Our results showed that patients with previous thrombotic events (group II) had higher levels of the IL-2, IL-4, IL-5, and IFN-γ when compared to those in group I. Furthermore, a different cytokine signature was detected in dialyzed patients according to previous occurrences or not of thrombotic events, suggesting that elevated levels of T-helper 1 and T-helper 2 cytokines might, at least in part, contribute to this complication. Hindawi 2017 2017-07-27 /pmc/articles/PMC5551539/ /pubmed/28819334 http://dx.doi.org/10.1155/2017/9678391 Text en Copyright © 2017 Danyelle Romana Alves Rios et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rios, Danyelle Romana Alves
Pinheiro, Melina Barros
de Oliveira Junior, Wander Valadares
Braga Gomes, Karina
Carvalho, Andréa Teixeira
Martins-Filho, Olindo Assis
Simões e Silva, Ana Cristina
Dusse, Luci Maria Sant'Ana
Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
title Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
title_full Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
title_fullStr Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
title_full_unstemmed Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
title_short Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
title_sort cytokine signature in end-stage renal disease patients on hemodialysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551539/
https://www.ncbi.nlm.nih.gov/pubmed/28819334
http://dx.doi.org/10.1155/2017/9678391
work_keys_str_mv AT riosdanyelleromanaalves cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT pinheiromelinabarros cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT deoliveirajuniorwandervaladares cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT bragagomeskarina cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT carvalhoandreateixeira cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT martinsfilhoolindoassis cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT simoesesilvaanacristina cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis
AT dusselucimariasantana cytokinesignatureinendstagerenaldiseasepatientsonhemodialysis